Year-End Termination Amendment

ML STRATEGIES, LLC for NOVARTIS PHARMACEUTICALS

Firm
Client
Income
$100,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S 484, Enhancing Drug Safety and Innovation Act of 2007, Title 1, drug safety; and Title 3, clinical trials registry and results. Federal Food, Drug and Cosmetic Act (21 USC 301), Chapters 1-9 as they relate to the review, approval and regulation of drugs biologics and devices.

LobbyistCovered position, as disclosed
MARK BUSE N/A
KENNETH CONNOLLY STAFF DIRECTOR SENATE EPW COMMITTEE
STEVEN IRIZARRY —
DAVID LEITER N/A
PATRICK D MARA N/A
ROBERT NEAL MARTIN N/A
JEREMY RABINOVITZ CHIEF OF STAFF - CONGRESSWOMAN LOIS CAPPS

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

* Medicare part D program (32 USC 1395w), drug coverage and reimbursement issues. H.R. 4, Medicare Prescription Drug Price Negotiation Act of 2007, all provisions included therein Medicare part D program (32 USC 1395w), drug coverage and reimbursement issues. H.R. 4, Medicare Prescription Drug Price Negotiation Act of 2007, all provisions included therein

LobbyistCovered position, as disclosed
MARK BUSE N/A
KENNETH CONNOLLY STAFF DIRECTOR SENATE EPW COMMITTEE
STEVEN IRIZARRY —
DAVID LEITER N/A
PATRICK D MARA N/A
ROBERT NEAL MARTIN N/A
JEREMY RABINOVITZ CHIEF OF STAFF - CONGRESSWOMAN LOIS CAPPS

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 4 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.